| アブストラクト | BACKGROUND: New trials indicated a potential of sodium-glucose cotransporter-2 inhibitors (SGLT2i) to reduce hyperkalemia, which might have important clinical implications, but real-world data are limited. Therefore, we examined the effect of SGLT2i on hyper- and hypokalemia occurrence using the FDA adverse event reporting system (FAERS). METHODS: The FAERS database was retrospectively queried from 2004q1 to 2021q3. Disproportionality analyses were performed based on the reporting odds ratio (ROR) and 95% confidence interval (CI). RESULTS: There were 84 601 adverse event reports for SGLT2i and 1 321 186 reports for other glucose-lowering medications. The hyperkalemia reporting incidence was significantly lower with SGLT2i than with other glucose-lowering medications (ROR, 0.83; 95% CI, 0.79-0.86). Reductions in hyperkalemia reports did not change across a series of sensitivity analyses. Compared with that with renin-angiotensin-aldosterone system inhibitors (RAASi) alone (ROR, 4.40; 95% CI, 4.31-4.49), the hyperkalemia reporting incidence was disproportionally lower among individuals using RAASi with SGLT2i (ROR, 3.25; 95% CI, 3.06-3.45). Compared with that with mineralocorticoid receptor antagonists (MRAs) alone, the hyperkalemia reporting incidence was also slightly lower among individuals using MRAs with SGLT-2i. The reporting incidence of hypokalemia was lower with SGLT2i than with other antihyperglycemic agents (ROR, 0.79; 95% CI, 0.75-0.83). CONCLUSION: In a real-world setting, hyperkalemia and hypokalemia were robustly and consistently reported less frequently with SGLT2i than with other diabetes medications. There were disproportionally fewer hyperkalemia reports among those using SGLT-2is with RAASi or MRAs than among those using RAASi or MRAs alone. |
|---|
| ジャーナル名 | Journal of cardiovascular medicine (Hagerstown, Md.) |
|---|
| 投稿日 | 2024/7/1 |
|---|
| 投稿者 | Yu, Meng; Zhao, Subei; Fan, Xiaoyun; Lv, Yuhuan; Xiang, Linyu; Li, Rong |
|---|
| 組織名 | Department of Endocrinology and Metabolism, The First Affiliated Hospital of;Chongqing Medical and Pharmaceutical College, The First Batch of Key Disciplines;on Public Health in Chongqing.;Department of Endocrinology, The First Affiliated Hospital of Chongqing Medical;University, Chongqing, China. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/38949149/ |
|---|
